Learning unaccusativity: Evidence for split intransitivity in child Spanish

We examine four features of unaccusativity in child-directed and child Spanish to determine what cues children might use to distinguish unaccusative and unergative verbs. Two are cross-linguistic lexico-semantic features: Subjects of unaccusatives are patients so we expect more inanimate subjects with unaccusatives; and unaccusatives tend to have an endpoint, hence may occur more frequently with perfective aspect. The other two are language-specific morphosyntactic features: VS order is grammatical with unaccusatives but not unergatives, and many unaccusative verbs allow/require the anticausative se clitic. We find all four features robustly in children's input and that even 1-2-year-olds show discriminate use of them

Complementos de verbos percetivos, causativos e de controlo de objeto em português europeu: dados da aquisição

In this paper we explore the acquisition of complements to object control, perception and causative verbs in European Portuguese. We present an exploratory research on young children elicited production of these complement types. Taking perception and causatives as R(aising) t(o) O(bject) verbs, we will be able to investigate children’s performance on raising and object control structures. The results show that both RtO and object control are avoided by pre-school children, who prefer less defective complements (which explains the low frequency of RtO structures) and structures with less theta-roles (which accounts for the problems in producing grammatical object control structures).info:eu-repo/semantics/publishedVersio

Aspects of the acquisition of object control and ECM-type verbs in European Portuguese

We investigate the acquisition of sentential complementation under causative, perception, and object control verbs in European Portuguese, a language rich in complement types including the typologically marked inflected infinitives. We tested 58 children between 3 and 5 years and 24 adults on a sentence completion task. The results support two main hypotheses concerning children’s initial biases in representing complement structure. The first pertains to argument structure - a verb selects only one internal (propositional) argument (Single Argument Selection Hypothesis), the other to syntactic structure – propositional complements are complete functional complements (Complete Functional Complement Hypothesis). These initial biases lead children to avoid raising-to-object and object control structures, in favor of finite complements and inflected infinitive complements, the latter appearing in both target and non-target contexts.info:eu-repo/semantics/publishedVersio

Aspects of the acquisition of object control and ECM-type verbs in European Portuguese

We investigate the acquisition of sentential complementation under causative, perception, and object control verbs in European Portuguese, a language rich in complement types including the typologically marked inflected infinitives. We tested 58 children between 3 and 5 years and 24 adults on a sentence completion task. The results support two main hypotheses concerning children’s initial biases in representing complement structure. The first pertains to argument structure - a verb selects only one internal (propositional) argument (Single Argument Selection Hypothesis), the other to syntactic structure – propositional complements are complete functional complements (Complete Functional Complement Hypothesis). These initial biases lead children to avoid raising-to-object and object control structures, in favor of finite complements and inflected infinitive complements, the latter appearing in both target and non-target contexts.info:eu-repo/semantics/publishedVersio

GATA6-AS1 Regulates Intestinal Epithelial Mitochondrial Functions, and its Reduced Expression is Linked to Intestinal Inflammation and Less Favourable Disease Course in Ulcerative Colitis

BACKGROUND AND AIMS: Widespread dysregulation of long non-coding RNAs [lncRNAs] including a reduction in GATA6-AS1 was noted in inflammatory bowel disease [IBD]. We previously reported a prominent inhibition of epithelial mitochondrial functions in ulcerative colitis [UC]. However, the connection between reduction of GATA6-AS1 expression and attenuated epithelial mitochondrial functions was not defined. METHODS: Mucosal transcriptomics was used to conform GATA6-AS1 reduction in several treatment-naïve independent human cohorts [n=673]. RNA pull-down followed by mass spectrometry was used to determine the GATA6-AS1 interactome. Metabolomics and mitochondrial respiration following GATA6-AS1 silencing in Caco-2 cells were used to elaborate on GATA6-AS1 functions. RESULTS: GATA6-AS1 showed predominant expression in gut epithelia using single cell datasets. GATA6-AS1 levels were reduced in Crohn\u27s disease [CD] ileum and UC rectum in independent cohorts. Reduced GATA6-AS1 lncRNA was further linked to a more severe UC form, and to a less favourable UC course. The GATA6-AS1 interactome showed robust enrichment for mitochondrial proteins, and included TGM2, an autoantigen in coeliac disease that is induced in UC, CD and coeliac disease, in contrast to GATA6-AS1 reduction in these cohorts. GATA6-AS1 silencing resulted in induction of TGM2, and this was coupled with a reduction in mitochondrial membrane potential and mitochondrial respiration, as well as in a reduction of metabolites linked to aerobic respiration relevant to mucosal inflammation. TGM2 knockdown in GATA6-AS1-deficient cells rescued mitochondrial respiration. CONCLUSIONS: GATA6-AS1 levels are reduced in UC, CD and coeliac disease, and in more severe UC forms. We highlight GATA6-AS1 as a target regulating epithelial mitochondrial functions, potentially through controlling TGM2 levels

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention